AML is a genetically heterogeneous disease, particularly in older patients. In patients older than 60 years, survival rates are variable after the most important curative approach, intensive ...

Panelists discuss how current risk stratification systems, particularly the European Leukemia Net 2022 classification for intensive therapy and the 2024 classification for lower intensity treatments, ...

Panelists explain that KMT2A-rearranged acute myeloid leukemia (AML) is an aggressive, molecularly distinct leukemia subtype marked by menin-dependent transcriptional dysregulation, poor response to ...

This multi-ancestry GWAS identified 4 novel loci that confer an increased risk of developing pediatric AML. Four novel loci were identified in a multi-ancestry genome-wide association study (GWAS) ...

Acute myeloid leukemia (AML) is a type of blood and bone marrow cancer. AML can affect people of any age, but it is most common in adults. AML occurs when bone marrow produces abnormal blood cells, ...